-
Nilufer Oguzhan,
Havva Cilan, Murat Sipahioglu,
Aydin Unal,
Ismail Kocyigit,
Feridun Kavuncuoglu,
Tamer Arikan,
Mahmut Akpek,
Deniz Elcik,
Omer Sahin,
Ebru Gulme,
Cigdem Pala,
Bulent Tokgoz,
Cengiz Utas,
Abdurrahman Oguzhan,
Oktay Oymak
[show abstract]
[hide abstract]
ABSTRACT: Aim: Contrast-induced nephropathy (CIN) is a relatively common and serious complication, which occurs after the administration of contrast materials to patients. Although the pathophysiology of CIN is not exactly understood, ischemia of the medulla, oxidative stress, and direct toxicity of the contrast material are some of the factors that are implicated for the pathogenesis of CIN. To date, the only therapy that reduces the risk of CIN is volume expansion. There are conflicting results about the roles of angiotensin receptor blockers (ARB) and calcium channel blockers (CCB) in studies on CIN. For this reason the aim of this study was to compare the efficiency of the prophylactic use of amlodipine/valsartan plus hydration versus hydration only for the prevention of CIN in patients undergoing coronary angiography (CAG). Patients and methods: We prospectively enrolled 90 patients whose baseline serum creatinine levels were under 2.1 mg/dL and who were scheduled for CAG. Patients were divided into two groups. Group I (n = 45), consisted of patients who received amlodipine/valsartan plus hydration, group II (n = 45) consisted of patients who received only hydration. The patients in group I were given amlodipine/valsartan 5/160 mg once a day for a total of 3 days, starting one day before CAG and continuing on the day of and the day after the procedure. A 1 mL/kg/h sodium chloride infusion was administered for a total of 24 h, starting 12 h before the procedure and 12 h after, in all patients. The baseline serum creatinine (S(cre)) level was obtained before the procedure and repeated 48 h after. CIN was defined as an increase of ≥0.5 mg/dL or an increase of >25% in baseline S(cre) on the second day after CAG. Results: The baseline clinical characteristics of the treatment groups were similar. Baseline S(cre) was 1.13 ± 0.33 in group I and 1.07 ± 0.23 mg/dL in group II (p = 0.31). There was a significant difference between the S(cre) levels 48 h after CAG between the two groups (1.18 ± 0.33-1.05 ± 0.23) (p = 0.03). The reason for this was the increase of S(cre) in group I. CIN occurred in 17.8% (8/45) of patients in group I and in 6.7% (3/45) of patients in group II (p = 0.197). In the diabetic subgroup, CIN occurred in 10.5% (2/19) of patients taking amlodipine/valsartan and in none of the patients in group II (p = 0.486). The Mehran scores of the patients who developed CIN were significantly higher than those patients who did not develop CIN. Conclusion: Amlodipine/valsartan therapy plus hydration did not reduce the risk of CIN in chronic kidney disease (CKD) Stage 2 patients who underwent elective CAG using a low-osmolar nonionic contrast medium. This is because there was a decrease in the glomerular filtration rate (GFR) using the Levey Modification of Diet in Renal Disease (MDRD) formula in the amlodipine/valsartan group and CIN occurred at a higher frequency in this group; ARBs and CCBs may be withheld before CAG in high-risk patients.
Renal Failure 02/2013; · 0.82 Impact Factor
-
Ozcan Orscelik,
Ismail Kocyigit,
Mahmut Akpek,
Orhan Dogdu,
Coskun Kaya,
Aydin Unal, Murat Sipahioglu,
Bulent Tokgoz,
Halit Zengin,
Oktay Oymak,
Mehmet Gungor Kaya
[show abstract]
[hide abstract]
ABSTRACT: BACKGROUND: Autosomal-dominant polycystic kidney disease (ADPKD) demonstrates cardiovascular manifestations, such as hypertension, myocardial infarction, and increased carotid intimae-media thickness. These complications are the main cause of morbidity and mortality in patients with ADPKD. Platelet activation and arterial stiffness are important manifestations that independently predict cardiovascular events. In the present study, we aimed to investigate the relation between arterial stiffness, mean platelet volume (MPV), and highly sensitive C-reactive protein (hs-CRP) in patients with normotensive polycystic kidney disease. METHODS: We included 30 normotensive subjects with ADPKD with an estimated glomerular filtration rate (eGFR) of 60 mL or more per minute per 1.73 m, 30 normotensive subjects with ADPKD with eGFR from 30 to 60 mL/min per 1.73 m, and 30 healthy controls in our study. Pulse wave velocity (PWV), eGFR, spot urine protein-creatinine ratio, MPV, and hs-CRP levels were measured in all participants. In addition, transthoracic echocardiography and ambulatory blood pressure monitoring were performed. RESULTS: Age, sex, biochemical markers, eGFR, hemoglobin level, and platelet count were similar in the ADPKD subjects and the controls. There were significant differences in MPV (9.8 ± 0.7, 8.7 ± 0.8, and 8.0 ± 0.5 femtolitre; P < 0.001) and hs-CRP (6.8 ± 3.0, 5.3 ± 2.7, and 2.6 ± 0.52 mg/L; P < 0.001) in the groups. Additionally, PWV values were increased from healthy subjects to ADPKD patients who have decreased eGFR (5.5 ± 1.1, 8.8 ± 1.6, and 10.8 ± 1.2 m/s; P for trend <0.001). There were significant positive correlations between PWV and MPV (r = 0.401; P = 0.002) and hs-CRP (r = 0.343; P = 0.007) in the patients with ADPKD. Additionally, PWV was independently predicted by MPV (β = 0.286; P = 0.007), proteinuria (β = 0.255; P = 0.001), eGFR (β = -0.479; P < 0.001), and hs-CRP (β = 0.379; P < 0.001) in the patients with ADPKD. In addition, eGFR, as a sign of severity of disease, was independently predicted by MPV (β = -0.325; P = 0.003), PWV (β = -0.471; P < 0.001), and hs-CRP (β = -0.269; P = 0.008). CONCLUSIONS: Our findings suggest that MPV and hs-CRP levels are associated with increased arterial stiffness in patients with early-stage ADPKD and those with late-stage ADPKD. Also, MPV and hs-CRP were independently associated with the severity of ADPKD.
Journal of Investigative Medicine 01/2013; · 1.96 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The central nervous system (CNS) toxicity of fluoroquinolones is well known but usually occurs benign. In the literature, there are a few number of severe CNS toxicity cases related to fluoroquinolones. Levofloxacin is a third-generation fluorinated quinolone antibiotic, is the active levo stereoisomer of ofloxacin, and has one of the most favorable adverse reaction profiles. We describe a case of delirium associated with levofloxacin in a 55-year-old man who was hospitalized in our medical clinic for pneumonia.
Renal Failure 03/2012; 34(5):634-6. · 0.82 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Peritonitis is currently one of the leading complications of continuous ambulatory peritoneal dialysis (CAPD) treatment. Aminoglycosides and vancomycin are used in the treatment of CAPD peritonitis despite their potential risk for ototoxicity. N-acetylcysteine (NAC) is a molecule used in the treatment and prophylaxis of many diseases related to oxidative stress. The aim of this study was to examine whether ototoxicity due to antibiotics used in the treatment of CAPD peritonitis can be prevented by NAC.
Sixty patients, who first developed CAPD peritonitis attacks from February 2008 to April 2010 were included in this study. Patients were divided into two groups, those taking an additional NAC treatment (n = 30) and a control group (n = 30). Low- and high-frequency hearing function tests were performed on the two groups before treatment (baseline), at the end of the first (early follow-up) and the fourth week after the treatment (late follow-up). Total doses of vancomycin and amikacin were recorded.
There was no statistically significant difference between the groups in terms of hearing functions at the beginning. However, patients taking NAC had better hearing function test results 4 weeks after the treatment compared with those of the control group (P < 0.05). There were no statistical differences between posttreatment low-frequency hearing function tests conducted at the baseline and the first and the fourth weeks in patients taking NAC. The first and the fourth week's low-frequency hearing functions worsened when compared with the baseline low-frequency results in the control group (P < 0.001). It was found that NAC had a protective effect against ototoxicity on low-frequency (0.25-8 KHz) hearing functions. The first and the fourth week's high-frequency hearing functions improved when compared with baseline high-frequency hearing functions in patients taking NAC (P < 0.05), while they worsened. The first and fourth week's high-frequency tests worsened when compared with the baseline high-frequency tests in the control group (P < 0.001).
The present study suggests that intraperitoneal aminoglycoside and vancomycin administration in CAPD patients may cause low- and high-frequency hearing loss, and this ototoxic effect is related to the dose given. It was found that when the antioxidant NAC is administered alone, it prevents ototoxicity, associated with intraperitoneal amikacin and vancomycin in patients with CAPD peritonitis. In addition, it was revealed that NAC may also have a curative effect on impaired high-frequency hearing functions.
Nephrology Dialysis Transplantation 05/2011; 26(12):4073-8. · 3.40 Impact Factor
-
European journal of dentistry 05/2009; 3(2):155-7.
-
[show abstract]
[hide abstract]
ABSTRACT: The incidence of active tuberculosis in patients undergoing maintenance dialysis for a long time is considerably higher than that in general population. A 39-year-old male treated by hemodialysis three times a week for six months was admitted to the hospital with a painless mass palpable under his right areola. X-ray examination of chest showed a hyperintense lesion. Computed tomography revealed a cystic mass in the superior segment of inferior lobe near the thoracic vertebrae. Needle aspiration of the lesion revealed granulomas and acid-resistant bacteria. Anti-tuberculous therapy was therefore initiated. After eight months the patient was admitted back with paraplegia. Magnetic resonance imaging (MRI) revealed that the lesion defined by computed tomography (CT) was extending to the spinal duct and compressing the spinal cord. A tissue biopsy was performed and granulomas were identified. Mycobacterium tuberculosis grew in the culture. This case suggests that in areas with a high incidence of tuberculosis renal patients in a high-risk group should be examined periodically to exclude insidious infection and reduce morbidity and mortality.
International Urology and Nephrology 05/2009; 42(1):223-6. · 1.47 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The styloid process (SP) is a cylindrical, long cartilaginous bone located on the temporal bone. The normal SP length is approximately 20-30 mm. The styloid process elongation (SPE) can be assumed if either the SP or the adjacent stylohyoid ligament ossification shows an overall length in excess of 30 mm. Elongated SP is known as Eagle's syndrome when it causes clinical symptoms as neck and cervicofacial pain. It is supposed that this symptoms and signs are due to the compression of the SP on some neural and vascular structures. It may also cause stroke due to the compression of carotid arteries. This syndrome is diagnosed by both radiographical and physical examination. Instead of many hypotheses and studies, the exact etiology of elongated SP and the role of ectopic calcification are unknown. Ectopic calcification (EC) might have a role for the elongation of SP. Abnormal calcium (Ca), phosphorus (P) and vitamin D metabolism is very common in patients with end-stage renal disease (ESRD). Therefore, this calcification in nonosseous soft tissue due to abnormal serum Ca and P levels is commonly associated with this disorder. EC due to the abnormality in this metabolism which is related to the duration of dialysis is also very important for this calcification. Therefore, a study in patients with ESRD investigating the prevalence of SP and the correlation between dialysis period and the SP length may help us explaining the role of EC in the elongation of SP. Because, this disease might be a good model for the investigation of the EC in this elongation. However, further studies and large samples are also needed to clarify the etiology of this disorder.
European journal of dentistry 08/2008; 2(3):224-8.
-
[show abstract]
[hide abstract]
ABSTRACT: Altered renal vasodilatation and oxidative stress are important mechanisms of contrast-induced nephropathy (CIN). The aim of the present study was to assess the effect of nebivolol, a beta blocker, on prevention of CIN. We hypothesized that nebivolol may prevent CIN due to its renal vasodilatation and antioxidant effects.
Thirty-two Wistar-albino rats were divided into four groups (n = 8 each): control (C), contrast media (CM), nebivolol (N), and nebivolol + contrast media (NCM). CIN was induced by administration of intravenous high-osmolar contrast media diatrizoate (6 ml/kg) after 72 h of dehydration. Nebivolol (2 mg/kg) was given internally once daily for 5 days. Kidney function parameters, nitric oxide metabolites and oxidative stress markers were measured. Kidneys were excised for pathological evaluation.
The decrease of creatinine clearance was 0.180 +/- 0.11 mg/dl in CM, and 0.030 +/- 0.10 mg/dl in NCM (P = 0.01). Microproteinuria was ameliorated using nebivolol (P = 0.001). Serum protein carbonyl content, malonyldialdehyde and kidney thiobarbituric acid-reacting substances levels were higher in CM than in C (P = 0.003, P < 0.001 and P = 0.034, respectively) and serum thiol was lower in CM than in C (P = 0.001). However, oxidative stress markers were similar in NCM and C. Diatrizoate decreased kidney nitrite levels, but nebivolol increased them (P = 0.027). Nebivolol attenuated the tubular necrosis, proteinaceous casts and medullary congestion, although significant protective effects, were observed in tubular necrosis (P = 0.001) and proteinaceous cast (P < 0.001).
This study demonstrated the protective role of nebivolol against CIN.
Nephrology Dialysis Transplantation 03/2008; 23(3):853-9. · 3.40 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Today atherosclerotic diseases are among the most important causes of death in the world. Epidemiological, clinical, genetic, experimental and pathological studies have clearly shown the role of lipoproteins in atherosclerosis. LDL is the major atherogenic lipoprotein and has been defined as the primary target of lipid lowering treatment by NCEP. Although the level of LDL, the primary target in the treatment of dyslipidemia, has been set as below 100 mg/dl in coronary heart diseases (CHD) and CHD risk equivalents, this level has been pulled down to below 70 mg/dl for the group defined as very high risk group by the ATP (Adult Treatment Panel) guide that has been updated following the new clinical studies. As we already know, cholesterol is the precursor of glucocorticoids, mineralocorticoids and sex steroids, besides being a structural component of the cell membrane. Both adrenal and non-adrenal (ovarian+testicular) all steroid hormones are primarily synthesized using the LDL-cholesterol in the circulation. In addition to this, there is 'de novo' cholesterol synthesis in both the adrenals and gonads controlled by the HMG-CoA reductase enzyme. A third pathway, which under normal circumstances has little contribution as compared to the first two, is the use of circulatory HDL-cholesterol by the adrenal and gonadal tissues for the synthesis of steroids. Our knowledge on extremely lowered LDL levels is quite limited. However, since statins both decrease circulatory LDL and inhibit de novo cholesterol synthesis, they are likely to affect the synthesis of steroid hormones.
Medical Hypotheses 02/2007; 69(1):104-12. · 1.39 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Aim: To investigate the prevalence of pulmonary arterial hypertension (PAH) and the possible contributing factors for PAH in patients receiving regular continuous ambulatory peritoneal dialysis (CAPD). Patients and
The study included 135 CAPD patients and 15 disease-free controls. Patients that had chronic obstructive pulmonary disease, severe mitral or aortic valve disease, connective tissue disease, history of pulmonary embolism, left ventricular ejection fraction <50%, or chest wall or parenchymal lung disease were excluded. All patients and controls were examined using echocardiography and bioelectrical impedance analysis. PAH was defined as systolic pulmonary artery pressure (PAP) >35 mmHg at rest.
Mean systolic PAP was higher in the CAPD patients than in the controls (19.66 +/- 11.66 vs 14.27 +/- 4.55 mmHg, p = 0.001). PAH was detected in 17 (12.6%) of the 135 CAPD patients. Mean systolic PAP was significantly higher in patients with PAH than in those without PAH (42.00 +/- 9.13 vs 16.44 +/- 7.83 mmHg, p = 0.001). Serum albumin level and ejection fraction were lower in patients with PAH than in those without PAH (p = 0.001 and 0.003 respectively). The ratio of extracellular water/total body water (ECW/TBW), which can reflect hydration status, was significantly higher in patients with PAH than in those without PAH (p = 0.008). In the PD group, no patients were hypovolemic; 51 (37.8%) of the 135 PD patients were hypervolemic and 84 (62.2%) were normovolemic. Only 3 of the 17 patients with PAH were normovolemic; the rest were hypervolemic. Mean systolic PAP was significantly higher in hypervolemic PD patients (24.57 +/- 14.19 mmHg) than in normovolemic PD patients (16.68 +/- 7.61 mmHg) (p = 0.001). PAP correlated with ECW/TBW (r = 0.317, p = 0.001) and left ventricular mass index (LVMI; r = 0.286, p = 0.001). On the other hand, it inversely correlated with serum albumin level (r = -0.281, p = 0.001), hemoglobin level (r = -0.165, p = 0.044), and ejection fraction (r = -0.263, p = 0.001). Serum albumin level, ECW/TBW, and LVMI were found in multivariate analysis to be independent risk factors for PAP.
PAH is a frequent cardiovascular complication in CAPD patients. Serum albumin level, hypervolemia, and LVMI are major risk factors for PAH. Therefore, strategies for treatment of hypervolemia, left ventricular hypertrophy, and hypoalbuminemia should be enhanced to prevent the development of PAH in CAPD patients.
Peritoneal dialysis international: journal of the International Society for Peritoneal Dialysis 29(2):191-8. · 2.10 Impact Factor
